Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer
- PMID: 31268539
- PMCID: PMC6613289
- DOI: 10.1001/jamanetworkopen.2019.6562
Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer
Abstract
Importance: The association between androgen deprivation therapy (ADT) exposure and dementia is uncertain.
Objective: To analyze the association between ADT exposure and diagnosis of Alzheimer disease or dementia among elderly men with prostate cancer.
Design, setting, and participants: This retrospective cohort study used data from the National Cancer Institute's Surveillance, Epidemiology, and End Results-Medicare linked database. Participants were 154 089 elderly men newly diagnosed with prostate cancer between 1996 and 2003. The analyses were conducted between November 1, 2018, and December 31, 2018.
Exposure: Androgen deprivation therapy.
Main outcomes and measures: Patients receiving ADT within 2 years of prostate cancer diagnosis were identified. Survival analysis was used to determine the association between ADT exposure and diagnosis of Alzheimer disease or dementia in the follow-up period. Propensity score and instrumental variable approaches were used to minimize measured and unmeasured selection bias. The association by dose of ADT was also examined.
Results: Of the 295 733 men diagnosed with prostate cancer between 1996 and 2003, 154 089 met the study criteria. Of these, 62 330 (mean [SD] age, 76.0 [6.0] years) received ADT within 2 years of prostate cancer diagnosis, and 91 759 (mean [SD] age, 74.3 [6.0] years) did not receive ADT. Mean (SD) follow-up was 8.3 (4.7) years. Exposure to ADT, compared with no ADT exposure, was associated with a diagnosis of Alzheimer disease (13.1% vs 9.4%; difference, 3.7%; 95% CI, 3.3%-3.9%; P < .001; hazard ratio [HR], 1.14; 95% CI, 1.10-1.18) and dementia (21.6% vs 15.8%; difference, 5.8%; 95% CI, 5.4%-6.2%; P < .001; HR, 1.20; 95% CI, 1.17-1.24). For 1 to 4 doses of ADT, the HR was 1.19 (95% CI, 1.15-1.24) for Alzheimer disease and 1.19 (95% CI, 1.15-1.23) for dementia. For 5 to 8 doses of ADT, the HR was 1.28 (95% CI, 1.22-1.35) for Alzheimer disease and 1.24 (95% CI, 1.19-1.29) for dementia. For more than 8 doses of ADT, the HR was 1.24 (95% CI, 1.16-1.34) for Alzheimer disease and 1.21 (95% CI, 1.15-1.28) for dementia. The number needed to harm was 18 patients (95% CI, 17-19 patients) and 10 patients (95% CI, 9.5-11 patients) for Alzheimer disease and dementia, respectively.
Conclusions and relevance: Among elderly patients with prostate cancer, ADT exposure was associated with subsequent diagnosis of Alzheimer disease or dementia over a follow-up period of at least 10 years.
Conflict of interest statement
Figures
![Figure 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6613289/bin/jamanetwopen-2-e196562-g001.gif)
![Figure 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6613289/bin/jamanetwopen-2-e196562-g002.gif)
![Figure 3.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6613289/bin/jamanetwopen-2-e196562-g003.gif)
Similar articles
-
Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.Pharmacotherapy. 2018 Oct;38(10):999-1009. doi: 10.1002/phar.2168. Epub 2018 Sep 4. Pharmacotherapy. 2018. PMID: 30080934
-
Association Between Androgen Deprivation Therapy and Risk of Dementia.JAMA Oncol. 2017 Jan 1;3(1):49-55. doi: 10.1001/jamaoncol.2016.3662. JAMA Oncol. 2017. PMID: 27737437
-
Type of Androgen Deprivation Therapy and Risk of Dementia Among Patients With Prostate Cancer in Taiwan.JAMA Netw Open. 2020 Aug 3;3(8):e2015189. doi: 10.1001/jamanetworkopen.2020.15189. JAMA Netw Open. 2020. PMID: 32865575 Free PMC article.
-
Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis.Prostate Cancer Prostatic Dis. 2017 Sep;20(3):259-264. doi: 10.1038/pcan.2017.10. Epub 2017 Mar 28. Prostate Cancer Prostatic Dis. 2017. PMID: 28349979 Review.
-
Neuropsychiatric Impact of Androgen Deprivation Therapy in Patients with Prostate Cancer: Current Evidence and Recommendations for the Clinician.Eur Urol Focus. 2020 Nov 15;6(6):1170-1179. doi: 10.1016/j.euf.2020.05.014. Epub 2020 Jul 18. Eur Urol Focus. 2020. PMID: 32690473 Review.
Cited by
-
A Comprehensive Review and Androgen Deprivation Therapy and Its Impact on Alzheimer's Disease Risk in Older Men with Prostate Cancer.Degener Neurol Neuromuscul Dis. 2024 May 17;14:33-46. doi: 10.2147/DNND.S445130. eCollection 2024. Degener Neurol Neuromuscul Dis. 2024. PMID: 38774717 Free PMC article. Review.
-
Association between CNS-active drugs and risk of Alzheimer's and age-related neurodegenerative diseases.Front Psychiatry. 2024 Feb 29;15:1358568. doi: 10.3389/fpsyt.2024.1358568. eCollection 2024. Front Psychiatry. 2024. PMID: 38487578 Free PMC article.
-
Ligand-gated ion channels as potential biomarkers for ADT-mediated cognitive decline in prostate cancer patients.Mol Carcinog. 2024 Jun;63(6):1051-1063. doi: 10.1002/mc.23708. Epub 2024 Mar 14. Mol Carcinog. 2024. PMID: 38482990
-
Instrumental activities of daily living in older patients with metastatic prostate cancer: results from the meet-URO network ADHERE prospective study.Sci Rep. 2024 Feb 28;14(1):4949. doi: 10.1038/s41598-024-53581-4. Sci Rep. 2024. PMID: 38418470 Free PMC article.
-
Contemporary Systemic Therapy Intensification for Prostate Cancer: A Review for General Practitioners in Oncology.Curr Oncol. 2024 Feb 15;31(2):1047-1062. doi: 10.3390/curroncol31020078. Curr Oncol. 2024. PMID: 38392072 Free PMC article. Review.
References
-
- D’Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292(7):821-827. doi:10.1001/jama.292.7.821 - DOI - PubMed
-
- Roach M III, DeSilvio M, Lawton C, et al. ; Radiation Therapy Oncology Group 9413 . Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003;21(10):1904-1911. doi:10.1200/JCO.2003.05.004 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous